Holly Yancy, DO
Vascular Neurology · Scottsdale, AZNPI 1861658858
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (60.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 71.1% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $7,584 and has fallen 96.3% since, to $277 in 2025.
Across 191 payments — averaging $63.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$9K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$163
- Pfizer$125
- Sunovion Pharmaceuticals Inc.$122
- Novartis$118
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$7,30060%
- Travel & lodging$9037%
- Food & beverage$3,96933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 22 | $8,653 |
| AbbVie(2 entities) | 87 | $1,910 |
| Teva Pharmaceuticals USA, Inc. | 14 | $163 |
| Pfizer | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 6 | $122 |
| Novartis | 9 | $118 |
| Lilly USA, LLC | 4 | $116 |
| Saol Therapeutics Inc. | 1 | $114 |
| AstraZeneca | 5 | $90 |
| Lundbeck LLC | 5 | $86 |
| Eisai Inc. | 4 | $61 |
| CSL Behring | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Argenx US, Inc. | 2 | $49 |
| Avanir Pharmaceuticals, Inc. | 3 | $43 |
| Livanova USA, Inc. | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Biosense Webster, Inc. | 2 | $35 |
| Grifols USA, LLC | 1 | $29 |
| SK Life Science, Inc. | 2 | $27 |
| Zyla Life Sciences, Inc. | 2 | $26 |
| Upsher-smith Laboratories LLC | 2 | $26 |
| Merz North America, Inc. | 1 | $23 |
| UCB, Inc. | 1 | $22 |
| Abbott | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Aquestive Therapeutics, Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Promius Pharma LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few vascular neurology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 76 | $106,946 |
| Aimovig AutoinjectorErenumab-Aooe | 64 | $80,275 |
| Emgality PenGalcanezumab-Gnlm | 86 | $74,265 |
| QuliptaAtogepant | 36 | $55,104 |
| UbrelvyUbrogepant | 47 | $51,879 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 23 | $22,412 |
| ReyvowLasmiditan Succinate | 20 | $18,495 |
| Ajovy SyringeFremanezumab-Vfrm | 11 | $11,622 |
| Dihydroergotamine Mesylate | 11 | $4,583 |
| Zolmitriptan | 15 | $3,949 |
| Eletriptan HbrEletriptan Hydrobromide | 19 | $2,892 |
| Naratriptan Hcl | 27 | $1,117 |
| RizatriptanRizatriptan Benzoate | 35 | $774 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 25 | $742 |
| Acetazolamide ErAcetazolamide | 13 | $592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $1,910 | $106,98383 claims |
| PfizerNurtec Odt | $125 | $106,94676 claims |
| Lilly USA, LLCReyvow | $116 | $18,49520 claims |
| Upsher-smith Laboratories LLCTopiramate | $26 | $13919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other vascular neurology in Scottsdale
- Oana DumitrascuScottsdale$509
- Sneha JacobScottsdale$449
- Mohamed TelebMesa$137K
- Sushant KaleGoodyear$24K
- Swaraj SinghPhoenix$16K
- Fahad LaghariTucson$15K
- Ahmed El GengaihyGlendale$8K
- Lynn AshbyPhoenix$986
- Supreet KaurPhoenix$700
- Paige BanyasPhoenix$657
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.